

Table 1. Host-targeting agents against hepatitis C virus infection.

Step	Target	Compound	Stage of development	Reference
Entry	CD81	Anti-CD81 mAbs	Mouse model	[55]
	SR-BI	Anti-SR-BI mAbs	Mouse model	[56, 57]
		ITX5061	Phase 1b	ClinicalTrials.gov Identifier: NCT01165359
	EGFR	Erlotinib	Mouse model	[21]
	NPC1L1	Ezetimibe	Mouse model	[40]
Replication	miR122	Miravirsen/ SPC3649	Phase 2a	[23]
	HMGCoA reductase	Statins	Phase 2	[75, 76]
	Cyclophilin A	SCY-635	Phase 1	[87]
		Alisporivir/ Debio 025	Phase 3	[91]
Assembly	Glucosidase	MX-3253	Phase 2	[108]